Header Logo

Connection

JORGE CASTILLO to Myeloid Differentiation Factor 88

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Myeloid Differentiation Factor 88.
JORGE CASTILLO
Connection Strength
7.325
Myeloid Differentiation Factor 88
  1. How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
    View in: PubMed
    Score: 0.707
  2. Genomic Landscape of Waldenstr?m Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
    View in: PubMed
    Score: 0.637
  3. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
    View in: PubMed
    Score: 0.615
  4. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.546
  5. Novel approaches to targeting MYD88 in Waldenstr?m macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
    View in: PubMed
    Score: 0.530
  6. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
    View in: PubMed
    Score: 0.505
  7. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
    View in: PubMed
    Score: 0.485
  8. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr?m Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.
    View in: PubMed
    Score: 0.183
  9. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr?m macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
    View in: PubMed
    Score: 0.173
  10. Clinical application of genomics in Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
    View in: PubMed
    Score: 0.170
  11. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr?m macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
    View in: PubMed
    Score: 0.165
  12. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
    View in: PubMed
    Score: 0.159
  13. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.158
  14. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.158
  15. CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
    View in: PubMed
    Score: 0.153
  16. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656.
    View in: PubMed
    Score: 0.151
  17. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.144
  18. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.143
  19. Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
    View in: PubMed
    Score: 0.138
  20. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71.
    View in: PubMed
    Score: 0.137
  21. Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
    View in: PubMed
    Score: 0.137
  22. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.127
  23. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.122
  24. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.122
  25. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.121
  26. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
    View in: PubMed
    Score: 0.110
  27. Waldenstr?m macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
    View in: PubMed
    Score: 0.108
  28. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
    View in: PubMed
    Score: 0.053
  29. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Glob Oncol. 2022 08; 8:e2100380.
    View in: PubMed
    Score: 0.047
  30. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.045
  31. Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
    View in: PubMed
    Score: 0.044
  32. Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
    View in: PubMed
    Score: 0.040
  33. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.038
  34. Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
    View in: PubMed
    Score: 0.032
  35. Future therapeutic options for patients with Waldenstr?m macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
    View in: PubMed
    Score: 0.031
  36. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.031
  37. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.030
  38. Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.